盐酸菲洛普对大鼠前列腺增生的抑制作用

Inhibitory Effects of Phenoprolamine on Cystometry(in vivo ) and Bladder \=Contractility (in vitro) and on Benign Prostatic Hyperplasia

进行盐酸菲洛普（Ｐｈｅｎｏｐｒｏｌａｍｉｎｅ，ＰＨＥＮＯＰ）对大鼠膀胱内压及前列腺增生的药效学研究。结果发现，在离体兔膀胱颈平滑肌，苯肾上腺素（Ｐｈｅ）能增加平滑肌收缩力，ＰＨＥＮＯＰ能浓度依赖性地使Ｐｈｅ的量效曲线平行右移，且最大反应不变（ｐＡ２＝７．２４）；ＰＨＥＮＯＰ２５．０、５０．０ｍｇ／ｋｇ灌胃能改变正常麻醉大鼠膀胱内压图，使膀胱容积、排尿压、排尿阈值压显著降低；在用丙酸睾丸素引起大鼠前列腺增生的实验中，ＰＨＥＮＯＰ１２．５、２５．０及５０．０ｍｇ／ｋｇ灌胃４周还可抑制大鼠前列腺组织的增生。提示。

Pharmacodynamical study of Phenoprolamine (PHENOP) on bladder contractility and benign prostatic hyperplasia was performed in mice. PHENOP caused parallel rightward shifts of the phenylephrine (Phe) concentrationcontractile response curves and didn't suppress the maximal contractile response to Phe (pA2=724) in isolated rabbit urinary bladder smooth muscle DDPH decreased the parameters of cystometry in urethaneanesthetized rats Thirty min after PHENOP (250,500 mg/kg, ig) administration, bladder capacity, voiding pressure,voiding threshold pressure were significantly decreased In the experiment of testosterone propionatesinduced prostatic hyperplasia of mice, PHENOP (125,250 and 500 mg/kg, ig for 4 weeks) could also inhibit the development of benign prostatic hyperplasia in rat PHENOP may be of clinical values in the treatment of benign prostatic hyperplasia and improve the urinary flow in such cases